Pacira BioSciences
PCRX
Pacira BioSciences (PCRX) news
Recent news
Pacira Biosciences, Inc.: Truist Securities reinstates coverage with buy rating; price target $30
AInvest Wire · Aug 17, 2026Pacira Biosciences outlook FY revenue USD 735-760 million
AInvest Wire · Aug 4, 2026Pacira Biosciences reiterates FY2026 Exparel net product sales guidance $600 mln-$620 mln
AInvest Wire · Aug 4, 2026Pacira Biosciences Q2 revenue USD 192.4 million vs. IBES estimate USD 190.8 million
AInvest Wire · Aug 4, 2026Pacira Biosciences Q2 adjusted EBITDA USD 48.7 million
AInvest Wire · Aug 4, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.